Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion.

Détails

ID Serval
serval:BIB_C39C5A4BDD55
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion.
Périodique
Journal of Clinical Oncology
Auteur⸱e⸱s
Leyvraz S., Ohnuma T., Lassus M., Holland J.F.
ISSN
0732-183X
Statut éditorial
Publié
Date de publication
1985
Peer-reviewed
Oui
Volume
3
Numéro
10
Pages
1385-1392
Langue
anglais
Résumé
We undertook a phase 1 study of Carboplatin (CBDCA) on an intermittent single intravenous (IV) bolus (schedule A) and a 24-hour continuous infusion schedule (schedule B). Hydration and forced diuresis were not performed. Patients were not premedicated for anticipated vomiting. Thirty-eight adult patients with solid tumors received a total of 71 courses. In schedule A, doses were escalated from 20 to 600 mg/m2. The dose-limiting toxicity was myelosuppression. At doses of 270 mg/m2 and higher, leukopenia and thrombocytopenia were reproducibly seen. The dose of 600 mg/m2 was the maximally tolerated dose, producing severe thrombocytopenia (platelet counts less than 30,000/microL). Other toxicities included a fall in hemoglobin levels and tolerable nausea and vomiting. Schedule B produced comparable hematologic and emetogenic toxicities to those in schedule A. In three patients audiograms became abnormal with high-frequency hearing loss without overt deafness. Two patients developed hypomagnesemia without irreversible renal dysfunction. Patients with poor performance status, preexisting renal dysfunction, a third fluid space, or bone metastases seemed to develop increased hematologic toxicity. The recommended phase 2 dose for good risk patients is 400 mg/m2 IV bolus and for poor risk patients 270 mg/m2 IV bolus. Responses were seen in one patient each with head and neck carcinoma (partial response), small cell lung cancer (minor response), and breast cancer (minor response).
Mots-clé
Adult, Aged, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/toxicity, Carboplatin, Creatinine/blood, Drug Administration Schedule, Drug Evaluation, Female, Humans, Infusions, Parenteral, Injections, Intravenous, Leukopenia/chemically induced, Magnesium/blood, Male, Middle Aged, Nausea/chemically induced, Organoplatinum Compounds/administration & dosage, Organoplatinum Compounds/toxicity, Thrombocytopenia/chemically induced, Vomiting/chemically induced
Pubmed
Web of science
Création de la notice
28/01/2008 9:32
Dernière modification de la notice
20/08/2019 16:38
Données d'usage